Key takeaways
- Tirzepatide-type dual agonists run about 39 amino acids versus roughly 31 for single-target GLP-1 peptides like semaglutide.
- Triple agonists such as retatrutide add glucagon receptor activity on top of GLP-1 and GIP targeting.
- Longer peptide chains have more bonds that can degrade, so multi-target agonists need stricter cold storage after reconstitution.
- A crowded field of companies developing similar compounds increases synthesis variance on the research-chemical market, making third-party purity testing more important, not less.
- Reused needles or cartridge septa raise contamination risk more for complex, fragile multi-target peptides than for simpler ones.
In this article
Eli Lilly and Viking Therapeutics keep showing up in the same headlines because they're chasing the same target: better versions of a gut hormone called GLP-1. The financial press frames this as a stock story. For anyone actually handling these peptides on a bench, the real story is what's happening inside the molecule, and why that changes how carefully you need to treat the vial.
What GLP-1 actually is, and why everyone wants a bigger version of it
GLP-1, short for glucagon-like peptide-1, is a hormone your gut releases after a meal. It's part of a small family called incretins, which also includes GIP (glucose-dependent insulinotropic polypeptide). Both hormones bind receptors that help regulate insulin release and appetite signaling. Semaglutide, the molecule behind well-known GLP-1 drugs, is a single-target agonist: it's built to activate only the GLP-1 receptor, held together longer in the body than natural GLP-1 by chemical modifications.
Eli Lilly's tirzepatide moved past that single-target design. It's a dual agonist, engineered to activate both the GLP-1 and GIP receptors on the same molecule. Viking Therapeutics has been developing its own dual GLP-1/GIP candidate, which is why the two companies get compared directly. Lilly has also pushed further with retatrutide, a triple agonist that adds glucagon receptor activity on top of GLP-1 and GIP. Each added receptor target means a longer, more complex amino acid chain, not just a stronger dose of the same thing.
Bigger, more complex peptides are also more fragile ones
A longer peptide chain has more places where a bond can break. Multi-target agonists like tirzepatide and retatrutide are built from roughly 39-40 amino acids, compared to semaglutide's 31. That extra length, plus the specific modifications needed to hit multiple receptors, tends to make the molecule more sensitive to heat, light, and repeated freeze-thaw cycles. In practice, that means the margin for storage error shrinks as these compounds get more sophisticated.
This matters directly for reconstitution. When you add bacteriostatic water to a lyophilized (freeze-dried) peptide, you're rehydrating a fragile chain that can start losing structure the moment it's back in liquid form. A dual or triple agonist doesn't forgive sloppy technique the way a shorter, simpler peptide might.
What the research community gets wrong about GLP-1-class peptides
- Assuming all GLP-1-class vials store the same way. Multi-target agonists degrade faster at room temperature than single-target ones; refrigerate promptly after reconstitution and don't leave vials out during a bench session.
- Ignoring diluent quality because "it's just water." Bacteriostatic water that isn't properly preserved or has been opened too many times introduces contamination risk that shows up as cloudiness or reduced peptide activity over time.
- Treating a busy drug-development field as a purity signal. More companies racing to develop dual and triple agonists also means more synthesis routes on the research-chemical market, and more variance in third-party purity testing. A crowded field is not the same as a verified one.
- Skipping certificate-of-analysis checks on newer multi-target peptides. These molecules are harder to synthesize cleanly, so requesting HPLC (high-performance liquid chromatography) purity data and mass spec confirmation matters more here than for simpler, older peptides.
- Reusing needles or cartridge septa across reconstitution sessions. Every puncture is a chance for airborne contaminants to enter, and a fragile, complex peptide has less tolerance for that stress than a simpler one.
The bench takeaway from a stock-market story
The Lilly-versus-Viking coverage is really a proxy for a bigger shift: incretin-targeting peptides are getting structurally more complex as companies chase multi-receptor activity. That complexity is good for expanding what these molecules can do, but it raises the stakes for anyone reconstituting and storing them. A cold chain slip or a rushed reconstitution wastes more with a 39-amino-acid dual agonist than it would with a shorter, simpler peptide, both because the chain has more to lose and because these compounds tend to be pricier per vial.
None of this requires new equipment. It requires treating multi-target peptides with the level of care their structure demands: proper bacteriostatic water, a metal pen or accurate syringe for consistent draws, cold storage right after reconstitution, and a purity check before anything goes in the cartridge at all.
Frequently asked questions
What's the difference between GLP-1, GIP, and glucagon agonist peptides?
GLP-1 and GIP are gut hormones (incretins) involved in insulin regulation; glucagon is a separate hormone. Single agonists target one receptor, dual agonists target two (like GLP-1 and GIP), and triple agonists add a third target.
Are dual or triple agonist peptides harder to store than single-target ones?
Generally yes. Their longer amino acid chains have more bonds that can break down, making them more sensitive to heat, light, and freeze-thaw cycles than shorter single-target peptides.
How can I verify purity on a newer multi-target GLP-1 peptide?
Request a certificate of analysis with HPLC purity data and mass spectrometry confirmation. These longer, more complex chains are harder to synthesize cleanly, so verified testing matters more than with simpler peptides.
Prompted by this coverage at Google News →
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators
Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.
